Biophytis’ Combined Annual General Meeting Will Take Place on April 26, 2021 behind closed doors
Biophytis will hold its Annual General Meeting (AGM) on April 26, 2021, at 5.00 p.m. CET in Paris. Due to COVID-19 restrictions, the meeting will be closed to shareholders. Voting documents are available on the company’s website, and shareholders are urged to vote in advance via mail, proxy, or the VOTACCESS platform. Key deadlines include submitting votes by April 23 for mail or proxy and by April 25 for VOTACCESS. BPTS is listed on the Nasdaq Capital Market, with ongoing clinical trials focused on age-related diseases and COVID-19.
- Upcoming AGM schedule indicates structured corporate governance.
- Encouragement for remote voting shows adaptability to COVID-19 challenges.
- AGM closed to shareholders may lead to dissatisfaction among investors.
- Potential delays in postal voting due to the COVID-19 pandemic could affect shareholder participation.
Legally required documents for shareholders’ votes are available on Biophytis website
PARIS and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, will hold its combined Annual General Meeting (AGM) on April 26th 2021 at 5.00 p.m. CET at Sorbonne Université, 4 Place Jussieu, 75005 Paris.
As a result of restrictions placed on the movement and gatherings of persons due to the COVID-19 pandemic, the Company’s Combined General Meeting will be held behind closed doors without the physical presence of its shareholders, in accordance with the provisions of the French Decree no 2021-255 of March 9 2021.
The notice of meeting, comprising the agenda and the draft resolutions was published in the French official legal bulletin Bulletin des Annonces Légales Obligatoires (BALO) n° 30, dated March 10, 2021. This notice includes information on how to vote at the AGM, as well as the vote bulletin. All these documents are also available on the Company’s website (www.biophytis.com) Because the above-mentioned French Decree no 2021-255 of March 9 2021 had not yet been published at the time of publication of the draft resolutions in the BALO n° 30, dated March 10, 2021, such publication does not expressly mention that the meeting will be held behind closed doors. [An amended publication in the BALO will be made in order to clarify this.]
Shareholders are strongly encouraged to vote in advance of the AGM by (i) mail, (ii) by appointing the Chairman of the meeting as your proxy or (iii) via the secure online platform VOTACCESS. On account of the possible effect of the Covid-19 pandemic on postal delivery times, it is recommended to return your voting forms as soon as practicable, or to vote via VOTACCESS. All documents are also available on the Company’s website.
Please note that the voting forms should be submitted no later than:
Vote by proxy or by mail on paper:
- April 23 (3-day deadline before the Meeting) for appointing the proxy or voting on paper with the single form
Vote by proxy or by mail via Votaccess:
April 25 at 3.00 p.m. CET
Holders of American Depositary Shares (ADSs) will receive relevant documents from the Bank of New York Mellon (Depositary).
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS - ISIN: FR0012816825), and ADSs are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040). For more information visit www.biophytis.com
Disclaimer
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation risks described in our filings with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. In France, please also refer to the "Risk Factors" section of the Company's Annual 2019 Report and the Company’s Half Year 2020 Report available on BIOPHYTIS website (www.biophytis.com). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
evelyne.nguyen@biophytis.com
Media contact
Life Sci Advisors
Sophie Baumont/Chris Maggos/John Hodgson
E: sophie@lifesciadvisors.com
T: +33 6 27 74 74 49
FAQ
When is Biophytis' AGM scheduled?
How can shareholders vote at the Biophytis AGM?
What is the deadline to vote by mail for Biophytis' AGM?
What are the key deadlines for voting via VOTACCESS for Biophytis?
Where can I find the voting documents for Biophytis' AGM?
